Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig plus iberdomide in relapsed/refractory multiple myeloma
2024-512146-41-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, single-arm trial of etentamig and iberdomide in multiple myeloma (MM), sponsored by AbbVie Inc. Primary endpoint: Dose-limiting toxicities. Planned start Jul 2025; status: authorised.
02
Drugs
etentamigiberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-512146-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512146-41-00.